Melan-A/MART-1 Antibody (M2-9E3)

Western Blot: Melan-A/MART-1 Antibody (M2-9E3) [NBP2-15198] - Western Blot Analysis of COLO38 cell lysate using Melan-A/MART-1 Antibody (M2-9E3).

Immunohistochemistry-Paraffin: Melan-A/MART-1 Antibody (M2-9E3) [NBP2-15198] - Formalin-paraffin human melanoma stained with Melan-A Ab (M2-9E3). Note cytoplasmic staining of cells.

Immunohistochemistry-Paraffin: Melan-A/MART-1 Antibody (M2-9E3) [NBP2-15198] - Formalin-paraffin human melanoma stained with Melan-A Ab (M2-9E3). Note cytoplasmic staining of cells.

• Reactivity: Hu, Mu, Rt
• Applications: WB, Flow, ICC/IF, IHC
• Clone: M2-9E3
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.2 mg/ml

Melan-A/MART-1 Antibody (M2-9E3) Summary

• Description: 200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-33150)
  
  Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
• Immunogen: Recombinant Melan-A/MART-1 protein (Uniprot: Q16655)
• Localization: Cytoplasmic
• Marker: Melanoma Marker
• Specificity: This antibody recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This monoclonal antibody labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.
• Isotype: IgG2b Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: MLANA
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1-2 ug/million cells
  • Immunocytochemistry/ Immunofluorescence 1-2 ug/ml
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1-2 ug/ml
  • Western Blot 1-2 ug/ml
• Application Notes: Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
  Optimal dilution for a specific application should be determined.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 10 mM PBS with 0.05% BSA
• Preservative: 0.05% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: Protein A or G purified

Alternate Names for Melan-A/MART-1 Antibody (M2-9E3)

• Antigen LB39-AA
• Antigen SK29-AA
• Mart 1 Melan A
• MART-1
• MART1MART-1
• MelanA
• Melan-A
• melanoma antigen recognized by T-cells 1
• MLANA
• Protein Melan-A

Background

Melan-A also known as MART-1 (Melanoma Antigen Recognize by T cells 1), is an 18 kDa melanocyte differentiation antigen recognized by T cells. Melan-A is expressed in melanosomes and the endoplasmic reticulum. Melan-A is the most widely used marker for identifying malignant melanoma (Campoli, 2012), a highly aggressive and deadly form of skin cancer which may be curable when caught early. Melan-A specific monoclonal antibodies have utility for evaluating suspected melanocyte lesions by immunohistochemistry as they have both high sensitivity (75-92%) and specificity (95-100%) for melanoma (Campoli, 2012, Oshie, 2012).
The M2-9E3 antibody clone labels melanomas and other tumors showing melanocyte differentiation (Kawakami et al, 1997). The antibody has been highly characterized, including by immunohistochemistry, immunofluorescence, western blot and immunoprecipitation, and the specificity of the antibody for Melan-A has also been validated by Melan-A siRNA knockdown (Hoashi et al, 2005). Additionally, the Melan-A antibody has been used in combination with other melanocyte differentiation markers to help confirm or exclude melanocyte histogenesis (Collins, 2012; Mihic-Probst, 2012). It is important to note that Melan-A expression is not restricted to melanoma, and may also be detectable on some other type of tumors (reviewed in Campoli, 2012).
The exact eptiope recognized by the Melan-A antibody has not been mapped. However, the Melan-A epitope recognized by this antibody appears to be different than that recognized by the M2-7C10 Melan-A antibody clone (ABX-125A) (Kawakami, 1997). Researchers often use more than one antibody against a given specificity to help follow up and validate results. Hence, it may be useful to use both the ABX-126A and ABX-125A antibodies in parallel to obtain additional information about Melan-A expression.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Melan-A/MART-1 Antibody (NBP2-15198)(2)

Publications using NBP2-15198

• Zhu B, Chen S, Wang H et al. The protective role of DOT1L in UV-induced melanomagenesis Nat Commun 2018-01-17 [PMID: 29343685] (IF/IHC, Mouse)
• Mihic-Probst D, Ikenberg K, Tinguely M et al. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One. 2012-01-01 [PMID: 22442699]

Bioinformatics

• Gene Symbol: MLANA
• Entrez:
  • 2315(Human)
  • 77836(Mouse)
  • 293890(Rat)
• Uniprot:
  • Q16655()
  • Q16655()
  • Q16655()